Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer

References

• Campisi J, d’Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8:729 - 40; http://dx.doi.org/10.1038/nrm2233; PMID: 17667954
   PubMed Web of Science ®Google Scholar
• Carrassa L, Broggini M, Erba E, Damia G. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle 2004; 3:1177 - 81; http://dx.doi.org/10.4161/cc.3.9.1080; PMID: 15326376
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19:107 - 20; http://dx.doi.org/10.1038/cdd.2011.96; PMID: 21760595
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87:99 - 163; http://dx.doi.org/10.1152/physrev.00013.2006; PMID: 17237344
   PubMed Web of Science ®Google Scholar
• Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011; 11:503 - 11; http://dx.doi.org/10.1038/nrc3057; PMID: 21701512
   PubMed Web of Science ®Google Scholar
• Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 2003; 278:9100 - 6; http://dx.doi.org/10.1074/jbc.M210284200; PMID: 12509415
   PubMed Web of Science ®Google Scholar
• Berndtsson M, Hägg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer 2007; 120:175 - 80; http://dx.doi.org/10.1002/ijc.22132; PMID: 17044026
   PubMed Web of Science ®Google Scholar
• Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11:700 - 14; http://dx.doi.org/10.1038/nrm2970; PMID: 20823910
   PubMed Web of Science ®Google Scholar
• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7:573 - 84; http://dx.doi.org/10.1038/nrc2167; PMID: 17625587
   PubMed Web of Science ®Google Scholar
• Winter C, Albers P. Testicular germ cell tumors: pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 2011; 7:43 - 53; http://dx.doi.org/10.1038/nrendo.2010.196; PMID: 21116298
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31:1869 - 83; http://dx.doi.org/10.1038/onc.2011.384; PMID: 21892204
   PubMed Web of Science ®Google Scholar
• Köberle B, Tomicic MT, Usanova S, Kaina B. Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta 2010; 1806:172 - 82; PMID: 20647037
   PubMed Web of Science ®Google Scholar
• Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22:7265 - 79; http://dx.doi.org/10.1038/sj.onc.1206933; PMID: 14576837
   PubMed Web of Science ®Google Scholar
• Borst P, Rottenberg S, Jonkers J. How do real tumors become resistant to cisplatin?. Cell Cycle 2008; 7:1353 - 9; http://dx.doi.org/10.4161/cc.7.10.5930; PMID: 18418074
   PubMed Web of Science ®Google Scholar
• Beers MH. Lung carcinoma. In: Porter RS, Jones TV, eds. The Merck manual of diagnosis and therapy. Rahway: Merck & Co., Inc., 2008:2992.
   Google Scholar
• Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008; 100:1672 - 94; http://dx.doi.org/10.1093/jnci/djn389; PMID: 19033571
   PubMed Web of Science ®Google Scholar
• Panaretakis T. Cisplatin-induced apoptosis and development of resistance are transcriptionally distinct processes. Cell Cycle 2012; 11:3723; http://dx.doi.org/10.4161/cc.22114; PMID: 22983001
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T, et al. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep 2012; 2:257 - 69; http://dx.doi.org/10.1016/j.celrep.2012.06.017; PMID: 22854025
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Senovilla L, Eisenberg T, Carmona-Gutierrez D, Vacchelli E, et al. Independent transcriptional reprogramming and apoptosis induction by cisplatin. Cell Cycle 2012; 11:3472 - 80; http://dx.doi.org/10.4161/cc.21789; PMID: 22918244
   PubMed Web of Science ®Google Scholar
• Yao Z, Szabadkai G. Transcriptional profiling of apoptosis: cell death classification moves toward the systems era. Cell Cycle 2012; 11:3721 - 2; http://dx.doi.org/10.4161/cc.22116; PMID: 22982998
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Marsili S, Vitale I, Senovilla L, Michels J, Garcia P, et al. Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. Cell Cycle 2013; 12:417 - 21; http://dx.doi.org/10.4161/cc.23275; PMID: 23287530
   PubMed Web of Science ®Google Scholar
• Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res 2013; In press
   Google Scholar
• Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 2012; 13:411 - 24; http://dx.doi.org/10.1038/nrm3376; PMID: 22713970
   PubMed Web of Science ®Google Scholar
• Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7:517 - 28; http://dx.doi.org/10.1038/nrm1963; PMID: 16829982
   PubMed Web of Science ®Google Scholar
• Jagtap P, Szabó C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005; 4:421 - 40; http://dx.doi.org/10.1038/nrd1718; PMID: 15864271
   PubMed Web of Science ®Google Scholar
• Villanueva T. Anticancer drugs: Expanding the horizons of PARP inhibitors. Nat Rev Drug Discov 2010; 9:919; http://dx.doi.org/10.1038/nrd3335; PMID: 21119729
   PubMed Web of Science ®Google Scholar
• Annunziata CM, O’Shaughnessy J. Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res 2010; 16:4517 - 26; http://dx.doi.org/10.1158/1078-0432.CCR-10-0526; PMID: 20823142
   PubMed Web of Science ®Google Scholar
• Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010; 10:293 - 301; http://dx.doi.org/10.1038/nrc2812; PMID: 20200537
   PubMed Web of Science ®Google Scholar
• Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376:245 - 51; http://dx.doi.org/10.1016/S0140-6736(10)60893-8; PMID: 20609468
   PubMed Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376:235 - 44; http://dx.doi.org/10.1016/S0140-6736(10)60892-6; PMID: 20609467
   PubMed Web of Science ®Google Scholar
• McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66:8109 - 15; http://dx.doi.org/10.1158/0008-5472.CAN-06-0140; PMID: 16912188
   PubMed Web of Science ®Google Scholar
• Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000; 6:2860 - 7; PMID: 10914735
   PubMed Web of Science ®Google Scholar
• Clark CC, Weitzel JN, O’Connor TR. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther 2012; 11:1948 - 58; http://dx.doi.org/10.1158/1535-7163.MCT-11-0597; PMID: 22778154
   PubMed Web of Science ®Google Scholar
• Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol 2012; 9:144 - 55; http://dx.doi.org/10.1038/nrclinonc.2012.3; PMID: 22330686
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366:1382 - 92; http://dx.doi.org/10.1056/NEJMoa1105535; PMID: 22452356
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 2009; 16:1093 - 107; http://dx.doi.org/10.1038/cdd.2009.44; PMID: 19373242
   PubMed Web of Science ®Google Scholar
• Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov 2011; 10:221 - 37; http://dx.doi.org/10.1038/nrd3373; PMID: 21358741
   PubMed Web of Science ®Google Scholar
• Harbron C. A flexible unified approach to the analysis of pre-clinical combination studies. Stat Med 2010; 29:1746 - 56; http://dx.doi.org/10.1002/sim.3916; PMID: 20572122
   PubMed Web of Science ®Google Scholar
• Banáth JP, Olive PL. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 2003; 63:4347 - 50; PMID: 12907603
   PubMed Web of Science ®Google Scholar
• Zhang P, Castedo M, Tao Y, Violot D, Métivier D, Deutsch E, et al. Caspase independence of radio-induced cell death. Oncogene 2006; 25:7758 - 70; http://dx.doi.org/10.1038/sj.onc.1209744; PMID: 16862186
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Zamzami N, de La Motte Rouge T, Lemaire C, Brenner C, Kroemer G. Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis 2007; 12:803 - 13; http://dx.doi.org/10.1007/s10495-007-0720-1; PMID: 17294081
   PubMed Web of Science ®Google Scholar
• Berglind H, Pawitan Y, Kato S, Ishioka C, Soussi T. Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Cancer Biol Ther 2008; 7:699 - 708; http://dx.doi.org/10.4161/cbt.7.5.5712; PMID: 18277095
   PubMed Web of Science ®Google Scholar
• Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M, et al. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res 1998; 26:205 - 13; http://dx.doi.org/10.1093/nar/26.1.205; PMID: 9399837
   PubMed Web of Science ®Google Scholar
• Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28:622 - 9; http://dx.doi.org/10.1002/humu.20495; PMID: 17311302
   PubMed Web of Science ®Google Scholar
• Vitale I, Senovilla L, Jemaà M, Michaud M, Galluzzi L, Kepp O, et al. Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos. EMBO J 2010; 29:1272 - 84; http://dx.doi.org/10.1038/emboj.2010.11; PMID: 20186124
   PubMed Web of Science ®Google Scholar
• Mullen P. PARP cleavage as a means of assessing apoptosis. Methods Mol Med 2004; 88:171 - 81; PMID: 14634228
   PubMedGoogle Scholar